Patents by Inventor Xiao-Hui Liu

Xiao-Hui Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10515724
    Abstract: A method and a system for determining an association of at least one biological feature with a medical condition utilizes the novel L1/2 penalized network-constraint regression model to achieve an improved biological analysis, in particular by solving high-dimensional problems. The method and the system of the present invention attain high accuracy and preciseness.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: December 24, 2019
    Assignee: MACAU UNIVERSITY OF SCIENCE AND TECHNOLOG
    Inventors: Yong Liang, Hai-Hui Huang, Xiao-Ying Liu
  • Patent number: 10438699
    Abstract: A system and a method for determining an association of one or more biological features with a medical condition provides empirical results and simulations confirming that the involvement of both L1/2-regularized logistic regression and L2-regularized logistic regression in the regression model is highly competitive against usual approaches like Lasso, L1/2, SCAD-L2, and Elastic net in analyzing high dimensional and low sample sizes data.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: October 8, 2019
    Assignee: MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Yong Liang, Hai-Hui Huang, Xiao-Ying Liu
  • Patent number: 8710057
    Abstract: The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II): or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: April 29, 2014
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: David J. Bearss, Xiao-Hui Liu, Hariprasad Vankayalapati, Yong Xu
  • Patent number: 8445502
    Abstract: The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: May 21, 2013
    Assignee: Astex Pharmaceuticals, Inc.
    Inventors: David J. Bearss, Rajashree Joshi-Hangal, Xiao-Hui Liu, Pasit Phiasivongsa, Sanjeev G. Redkar, Hariprasad Vankayalapati
  • Publication number: 20110281863
    Abstract: The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II): or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.
    Type: Application
    Filed: July 21, 2011
    Publication date: November 17, 2011
    Applicant: SuperGen, Inc.
    Inventors: David J. Bearss, Xiao-Hui Liu, Hariprasad Vankayalapati, Yong Xu
  • Publication number: 20110086112
    Abstract: The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer.
    Type: Application
    Filed: October 18, 2010
    Publication date: April 14, 2011
    Applicant: SUPERGEN, INC.
    Inventors: David J. Bearss, Rajashree Joshi-Hangal, Xiao-Hui Liu, Pasit Phiasivongsa, Sanjeev G. Redkar, Hariprasad Vankayalapati
  • Patent number: 7820684
    Abstract: The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer.
    Type: Grant
    Filed: March 3, 2008
    Date of Patent: October 26, 2010
    Assignee: SuperGen, Inc.
    Inventors: David J. Bearss, Rajashree Joshi-Hangal, Xiao-Hui Liu, Pasit Phiasivongsa, Sanjeev G. Redkar, Hariprasad Vankayalapati
  • Publication number: 20100227861
    Abstract: The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II): or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.
    Type: Application
    Filed: May 21, 2010
    Publication date: September 9, 2010
    Applicant: SUPERGEN, INC.
    Inventors: David J. Bearss, Xiao-Hui Liu, Hariprasad Vankayalapati, Yong Xu
  • Publication number: 20100204221
    Abstract: Compounds represented by Formula (I): are useful in treating diseases, such as cancer, that are mediated and/or associated (at least in part) with Axl kinase. The compounds can be formulated as pharmaceutically acceptable compositions for administration to a subject in need thereof.
    Type: Application
    Filed: February 8, 2010
    Publication date: August 12, 2010
    Inventors: Hariprasad Vankayalapati, Xiao-Hui Liu, William Merton Hewitt, Eric Scott Gourley, Yong Xu, Bhasker Aavula
  • Patent number: 7750007
    Abstract: The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II): or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.
    Type: Grant
    Filed: November 6, 2007
    Date of Patent: July 6, 2010
    Assignee: SuperGen, Inc.
    Inventors: David J. Bearss, Xiao-Hui Liu, Hariprasad Vankayalapati, Yong Xu
  • Publication number: 20080261988
    Abstract: The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II): or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.
    Type: Application
    Filed: November 6, 2007
    Publication date: October 23, 2008
    Applicant: SUPERGEN, INC.
    Inventors: David J. Bearss, Xiao-Hui Liu, Hariprasad Vankayalapati, Yong Xu
  • Publication number: 20080226747
    Abstract: The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer.
    Type: Application
    Filed: March 3, 2008
    Publication date: September 18, 2008
    Applicant: SUPERGEN, INC.
    Inventors: David J. Bearss, Rajashree Joshi-Hangal, Xiao-Hui Liu, Pasit Phiasivongsa, Sanjeev G. Redkar, Hariprasad Vankayalapati
  • Publication number: 20080214558
    Abstract: Pyrimidine-2,4-diamines derivatives having activity as JAK2 kinase inhibitors are disclosed, as well as pharmaceutical compositions and methods for using the same in the treatment of cancer and other JAK2 kinase-associated conditions.
    Type: Application
    Filed: February 29, 2008
    Publication date: September 4, 2008
    Applicant: SUPERGEN, INC.
    Inventors: Hariprasad Vankayalapati, Xiao-Hui Liu, David J. Bearss
  • Publication number: 20080207632
    Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer, such as Aurora kinase-expressing cancers and Axl kinase-expressing cancers. Compounds of the invention have the following structure: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Z, L2 and w are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.
    Type: Application
    Filed: October 31, 2007
    Publication date: August 28, 2008
    Applicant: SUPERGEN, INC.
    Inventors: David J. Bearss, Cory L. Grand, Xiao-Hui Liu, Hariprasad Vankayalapati